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Delayed graft function (DGF) is an early complication of kidney transplantation (KT) associ-
ated with increased risk of early loss of graft function. DGF increases using kidneys from
extended criteria donors (ECD). NGAL is a 25KDa protein proposed as biomarker of acute
kidney injury. The aim of this study was to investigate the role of NGAL as an early and
accurate indicator of DGF and Tacrolimus (Tac) toxicity and as a mediator of tissue regener-
ation in KT from ECD.
Methods
We evaluated plasma levels of NGAL in 50 KT patients from ECD in the first 4 days after
surgery or after Tac introduction.
Results
Plasma levels of NGAL at day 1 were significantly higher in DGF group. In the non DGF
group, NGAL discriminated between slow or immediate graft function and decreased more
rapidly than serum creatinine. NGAL increased after Tac introduction, suggesting a role as
marker of drug toxicity. In vitro, hypoxia and Tac induced NGAL release from tubular epithe-
lial cells (TEC) favoring an autocrine loop that sustains proliferation and inhibits apoptosis
(decrease of caspases and Bax/Bcl-2 ratio).
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Conclusions
NGAL is an early and accurate biomarker of graft function in KT from ECD favoring TEC
regeneration after ischemic and nephrotoxic injury.
Introduction
Kidney Transplantation (KT) represents the most effective treatment for End Stage Renal Dis-
ease [1]. When compared to dialysis, KT improves patients survival, quality of life, cardiovas-
cular morbidity and diminishes infectious complications [2,3]. However, several
immunological and non-immunological causes lead to the deterioration of kidney graft func-
tion. Ischemia-reperfusion injury is the main cause of delayed graft function (DGF), an early
complication of KT usually defined as the need for dialysis in the first week after the procedure.
DGF is associated with the loss of graft function also due to an increased risk of acute rejection
and it is a cause of reduced long term graft survival [4]. The incidence of DGF has been increas-
ing over the last years for the use of kidneys from extended criteria donors (ECD) [5,6].
Recently, a broad variety of biomarkers including KIM-1, IL-18 and Neutrophil Gelatinase
Associated Lipocalin (NGAL) have been proposed for the early detection of DGF. Among
these, NGAL is a 25 KDa protein belonging to lipocalins, a family of proteins characterized by
a hydrophobic cup-shaped binding site. NGAL has a high affinity for siderophora and it is
involved in neutrophilic response to infections and in the processes of tissue differentiation
and repair through iron chelation or delivering [7]. It has been previously shown that NGAL is
expressed in tubular epithelial cells and that it is massively and rapidly up-regulated after ische-
mic, toxic or septic acute kidney injury (AKI) [8,9]. Moreover it has been recently demon-
strated that NGAL can act as a tubular growth factor decreasing cell damage in experimental
kidney ischemia-reperfusion injury [7,10].
The aim of this study is to evaluate whether plasma NGAL is an early and accurate bio-
marker of graft function in KT from ECD. For this purpose, we correlated plasma NGAL levels
after KT with the incidence of DGF. In addition, plasma NGAL was measured after tacrolimus
(Tac) administration to assess the early renal response to this nephrotoxic drug. In vitro, we
investigated the potential regenerative effect of NGAL on cultured human tubular epithelial
cells (TEC) exposed to hypoxia or incubated with therapeutic doses of Tac.
Material and Methods
Patients and clinical parameters
In this prospective monocentric study, we enrolled all consenting subjects who underwent KT
from ECD from November 2013 until recruitment of 50 patients (September 2014) in the “A.
Vercellone” Kidney Transplant Center in Torino, Italy. To assess if this selected group was rep-
resentative of our population of patients receiving a KT from ECD, this group was compared
to all the other patients fulfilling the same criteria in 2013–2014 (total 93). ECD were defined
according to Cristal City criteria: donors over 60 years of age or over 50 with at least two of the
following criteria: hypertension, serum creatinine> 132 mcmol/l (1.5mg/dl) or cerebro-vascu-
lar accident as cause of death [11]. Organ allocation was performed on the basis of histological
criteria according to Karpinski et al. [12]. Induction immunosuppressive regimen was as it fol-
lows: basiliximab 20 mg on day 0 and day 4, mycophenolate mophetil 2g/die and steroids. Tac
was given when serum creatinine reached 2.5 mg/dl (Tac target levels 12–15 ng/ml). The local
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ethic committee (Comitato Etico Interaziendale A.O.U. Città della Salute e della Scienza di
Torino—A.O. Ordine Mauriziano—A.S.L. TO1) approved study protocol; a written consent
was obtained from all KT recipients. None of the transplant donors were from a vulnerable
population and all donors or next of kin provided written informed consent that was freely
given in accordance to guidelines and standard procedures of AIRT (Associazione Inter-Regio-
nale Trapianto) and Italian National Transplant Center (Centro Nazionale Trapianti—CNT).
Delayed Graft Function (DGF) was defined as the need for dialysis during the first week
after KT [13]; non-DGF group was further divided in Slow Graft Function (SGF: serum
creatinine> 3 mg/dl on day 6 after KT) and Immediate Graft Function (IGF: serum
creatinine< 3 mg/dl on day 6 after KT) [14]. Ten patients with KT from living donors were
enrolled as controls.
We evaluated the following clinical parameters: A) recipient variables: age, sex, BMI, hyper-
tension, diabetes, dialysis duration (months), type of dialysis, peak PRA %, previous KT, type
of nephropathy; B) donor variables: age, BMI, serum creatinine, eGFR, hypertension, diabetes,
cause of death; C) KT procedure variables: cold ischemia time (CIT), HLA mismatches, pre-
transplant Karpinski biopsy score. We also estimated DGF risk using the prediction nomogram
proposed by Irish et al. [13] (http://www.transplantcalculator.com/DGF).
Moreover, a 10-year retrospective analysis (2002–2012) was performed to investigate the
difference of DGF incidence between KT from ECD and non-ECD in our center.
NGAL and Creatinine plasma levels
Patients plasma was collected immediately before surgery and in the first 24h after KT; samples
were centrifuged (1000g for 10 minutes) and quickly frozen at −80°C. NGAL was measured by
using a commercially available fluorimetric immunoassay (Triage kit, Alere Inc., San Diego,
CA). All samples were analyzed in duplicate; intra-assay and inter-assay coefficient of variation
were 11% and 13.5% respectively. NGAL was also evaluated in 4 consecutive days after KT (or
until the start of dialysis in the DGF group), before and 24h after CNI introduction.
Serum creatinine was measured by Alkaline Picrate colorimetric assay, (Jaffè method);
intra-assay and inter-assay coefficient of variation were 1.5% and 2.5% respectively.
In vitro studies
Human Tubular Cell Isolation and Culture. Primary cultures of human tubular epithelial
cells (TEC) were isolated and characterized as previously described [15]. TEC were grown in
RPMI 1640 (Life Technologies, Grand Island, NY) containing 10% FCS (Hyclone, Logan, UT)
and 2 mM glutamine (Life Technologies). In selected experiments TEC were cultured in hyp-
oxic conditions for 24h into an airtight humidified chamber flushed with a gas mixture contain-
ing 5% CO2, 94% N2, and 2% O2 at 20 atm, 37°C [16] or with 20 ng/ml Tac (Sigma Aldrich,
St. Louis, MO) for 24h. To investigate the activity of NGAL on TEC, 500ng/ml of recombinant
NGAL (R&D Systems, Minneapolis, MN) were added to cell cultures. Appropriate recombinant
NGAL concentration was chosen accordingly to values detected in our patients (see Results sec-
tion) and after performing a dose-response TEC proliferation assay (S1 Fig).
Gene and protein expression in TECs cultured in different experimental conditions.
Total RNA was isolated from TEC using the mirVana RNA isolation kit (Life Technologies).
RNA was quantified by spectrophotometer (Nanodrop ND-1000, Nanodrop, Wilmington, DE,
USA). First strand DNA was produced from 1μg of RNA using High cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA, USA) [17]. Quantitative Real time PCR (qRT—
PCR) was performed using the Power SYBR Green PCR Master Mix on a 96-well StepOnePlus
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Real Time System (Applied Biosystems). The following sequence-specific oligonucleotide
primers were used (MWG-Biotech AG, Ebersberg, Germany):
NGAL: forward 5'-CCT CCG TCC TGT TTA GGA AAA A-3'; reverse 5'-TCG TTA ATC
CAG GGT AAC TCT TAA TG-3';
GAPDH (control housekeeping gene): forward, 50-TGG AAG GAC TCA TGA CCA CAG T-30;
reverse 50-CAT CAC GCC ACA GTT TCC C-30;
Beta-Actin: forward, 5’-GAG TCC GGC CCC TCC AT-3’; reverse; 5’-GCA ACT AAG TCA
TAG TCC GCC TAG A-3’.
In all experiments, 2.5μg of cDNA template were used and thermal-cycling conditions were
as follows: activation of AmpliTaq Gold DNA Polymerase LD at 95°C for 10min, followed by
40 cycles of amplification at 95°C for 15sec and 60°C for 1min. Expression of mRNA levels was
detected by using relative Ct quantification analysis as follows:Delta(Ct) = Ct target NGAL—
Ct control housekeeping [18]. Relative NGAL expression was estimated by the formula: gene
expression = 2-Delta(Cτ). Both Beta-Actin and GAPDH were used as control housekeeping
genes.
NGAL, megalin and ZO-1 protein expression on TEC was evaluated by FACS and immuno-
fluorescence studies by using a rabbit polyclonal anti-human antibody (Santa Cruz Biotechnol-
ogy) and an appropriate FITC-conjugated secondary antibody.
NGAL levels were also determined by ELISA in TEC supernatants in different experimental
conditions (R&D Systems, Minneapolis, MN). Results were calculated after the generation of a
standard curve with appropriate controls and given as averages ± 1 SD.
TEC cytotoxicity and apoptosis assays. TEC were cultured onto 24-well plates (Falcon
Labware, Oxnard, CA) at a concentration of 5x104 cells/well and incubated with different sti-
muli and 250 μg/ml XTT (Sigma Aldrich) in a medium without phenol red. The absorption
values were measured in an automated spectrophotometer at 450 nm wavelength at different
time points [19].
TEC cultured in different experimental conditions were subjected to TUNEL assay (Apop-
Tag; Oncor, Gaithersburg, MD) in accordance with manufacturer’s instructions [19].
In selected experiments, TEC were seeded on 24-well plates and engineered to knock-down
megalin, the NGAL receptor, by transfection with 80 pM of specific siRNA (S1 File). Transfec-
tion with 80 pM of irrelevant siRNA was used as experimental control according to the manu-
facturer’s instructions (Santa Cruz Biotechnology). After 48 h, the knock-down of megalin was
verified by qRT-PCR, western blot (see above) and FACS analysis (S1 File) and cells were used
for XTT and TUNEL assays as previously described.
Western blot analysis. For Western blot, cells were detached with EDTA and lysed with a
50-mM Tris-HCl buffer containing 1% Triton X-100, 10μM/ml leupeptin, 10μM PMSF, and
100 U/ml aprotinin. After centrifugation of TEC lysates at 15000g, protein contents of the
supernatants were measured by the Bradford method: 30 μg of protein per lane was subjected
to SDS-PAGE (10%) and electroblotted onto nitrocellulose membrane filters. Blots were subse-
quently blocked with 5% nonfat milk in 20 mM Tris-HCl (pH 7.5), 500 mMNaCl, and 0.1%
Tween. Membranes were incubated overnight at 4°C with anti-bodies directed to human mega-
lin, Bax and Bcl-2 (Santa Cruz Biotechnology) at a concentration of 500 ng/ml. After washing
with 0.1% Tween, blots were stained for 1 h, RT with horse-radish peroxidase conjugated pro-
tein A (200 ng/ml; Amersham, Buckingamshire, UK), washed again with 0.1% Tween, devel-
oped with ECL detection reagents (Amersham), and exposed to X-Omat film (Eastman Kodak,
Rochester, NY).
Caspase-3, -8, and -9 Activities. The activities of caspase-3, -8, and-9 were assessed by
ELISA (Chemicon, Temecula, CA) on the basis of spectrophotometric detection of the cromo-
phore p-nitroanilide (pNA) after cleavage from the labeled substrate DEVD-pNA, which is
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recognized by caspases. TEC lysates were diluted with appropriate reaction buffers, and
DEVDpNA was added at final concentration of 50 M. Samples were analyzed with automated
ELISA reader at a wavelength of 405 nm. Each experiment was performed in triplicate.
TEC functional assays. Trans-epithelial electrical resistance (TEER) was used as indicator
of cell polarity. Cells were plated in transwells on collagen-coated polycarbonate membranes
(Corning Costar Corp., Cambridge, MA) and allowed to reach confluence before the addition
of stimuli. An epithelial volt-ohm meter (EVOM; World Precision Instruments, Sarasota, FL)
was used to determine TEER values as described previously [20]. All measures were performed
in triplicate and normalized for membrane area.
Protein uptake was studied after incubation of TEC with 50 mg/ml FITC-conjugated
human albumin at 37°C for 2h. After FITC-albumin challenge, TEC were washed with ice-cold
1x PBS and analyzed by FACS.
Statistical Analysis
Data analysis was performed with SPSS (Inc. Chicago IL, vers. 20.0.0). Distribution of variables
was assessed by skewness and kurtosis; continuous non-normal distributed data were described
using the median and range (min—max) and analyzed with Mann-Whitney test; normal dis-
tributed variables were described with mean and standard deviation and analyzed with two-
tails t-test or ANOVA depending on groups number. NGAL plasma levels were adjusted by
stepwise logistic regression multivariate analysis for potential confounding variables. Propor-
tion based analysis was performed with χ2 test. A p value<0.05 was considered significant.
Results
KT patients’ data analysis
DGF incidence and clinical parameters of the study group. On the basis of a retrospec-
tive study on 1180 KT performed in our centre between 2002 and 2012, we observed a signifi-
cant overall higher incidence of DGF in KT recipients from ECD (ECD 29.7% vs. non ECD
15.6%; p<0.001) (Fig 1A and 1B). We previously analysed plasma NGAL levels in a first cohort
of 25 kidney transplanted patients from ECD, observing that values>400 ng/ml were associ-
ated with DGF [21]. Therefore, we designed a prospective study in a second cohort of KT from
ECD performed in 2013–2014: the incidence of DGF in this study group was 28% (14/50). The
non-DGF group (n = 36) included 19 cases of SGF (53%) and 17 cases of IGF (47%); two
patients developed acute rejection before hospital discharge, one patient of the DGF group and
one of the IGF group. Comparison of donor-, recipient- and KT-associated variables between
the studied group (n = 50) and all other KT from ECD performed between 2013 and 2014
(n = 93) did not show any significant differences. For this reason, we considered our study
group as a representative sample of the whole KT population from ECD in our center
(Table 1). We did not observe any significant difference in DGF vs. non-DGF group regarding
donor and recipient age and co-morbidities, CIT, HLA-mismatches and donor pre-transplant
Karpinski biopsy score (Table 2). We also applied the risk prediction model for DGF proposed
by Irish et al. Values obtained by using the individual risk calculator were not significantly dif-
ferent between the DGF and the non-DGF group (DGF 0.23±0.06 vs. non-DGF 0.27±0.10;
p = 0.2) (Fig 2).
NGAL values predicted graft recovery and increased after Tac administration. Mean
NGAL levels in the DGF group were 662.7±97,2 ng/ml vs. 379.7±139.7 ng/ml in the non-DGF
group (p< 0.001) (Fig 3A). Pre-transplant levels of NGAL of all enrolled patients were similar
to those detected in the DGF group at day 1 post-transplantation (632±84ng/ml; p = 0,25). The
difference between DGF and non-DGF group was still significant in multivariate analysis after
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correcting NGAL values for day 1 serum creatinine, donor and recipient age, cold ischemia
time, donor diabetes and hypertension or histological score (p<0,01). Using the ROC curve,
we identified a level of NGAL of 532 ng/ml as the more sensitive and specific value to distin-
guish between DGF and non-DGF (sensitivity 90.9%; specificity 80.6%, AUC 0.94, Fig 3B). In
Fig 1. Number of KT performed (white bars) and relative DGF incidence (expressed as% of total KT in black bars) from 2002 to 2012 in KT from
ECD (A) or non-ECD (B). DGF incidence in KT from ECD was significantly higher than in KT from non-ECD (p<0.0001). ECD: extended criteria donors;
DGF: delayed graft function; KT: kidney transplantation.
doi:10.1371/journal.pone.0129279.g001
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Table 1. Comparison between study group and other patients underwent ECD KT between 2013 and 2014.
Study Group (n = 50) Other ECD KT (2013–2014) (n = 93) p
Donors’ variables
Age (years) 65.8 (SD = 68.7) 67.1 (SD = 8.91) 0.8
BMI (kg/m2) 25.4 (SD = 3.1) 25.5 (SD = 3.25) 0.81
eGFR (ml/min) 91.2 (SD = 25.3) 88.1 (SD = 8.9) 0.5
sCr (mg/dl) 0.78 (SD = 0.32) 0.82 (SD = 0.27) 0.6
Hypertension 64% (n = 32) 58% (n = 54) 0.54
Diabetes 10% (n = 5) 7.5% (n = 7) 0.62
Cause of death (n = 48/50) (n = 93/93)
- traumatic 32% (n = 16) 29% (n = 27) 0.5
- vascular 68% (n = 32) 71% n = (66)
Recipients’ variables
Age (years) 56.7 (SD = 9.3) 58.9 (SD = 9.6) 0.22
BMI (kg/m2) 24.2 (SD = 3.7) 24.6 (SD3.5) 0.51
Hypertension 71.4% (n = 35) 63.4% (n = 59) 0.53
Diabetes 18% (n = 9) 14% (n = 13) 0.56
Dialysis duration (months) 50.1 (SD = 62.14) 45.4 (SD = 31.6) 0.21*
Dialysis type
- hemodialysis 78% (n = 39) 63% (n = 59) 0,07
- peritoneal 22% (n = 11) 37% (n = 24)
PRA % 3.5 (SD = 13.1) 4.9 (SD = 14.5) 0.51
Gender
- male 42% (n = 21) 40% (n = 37) 0,36
- female 58% (n = 29) 60% (n = 56)
Previous KT 10% (n = 5) 13% (n = 12) 0,042
Discharge sCr (mg/dl) 1.93 (SD = 0.43) 1.97 (SD = 0.49) 0.69
Discharge pto (g/day) 0.57 (SD = 0.6) 0.51 (SD = 0.44) 0.57
Nephropathy (n = 49/50) (n = 93/93)
- glomerular 20% (n = 10) 27% (n = 24) 0.52
- tubule-interstitial 12% (n = 6) 14% (n = 13)
- vascular 14% (n = 7) 24.7% (n = 23)
- diabetes 8% (n = 4) 3.2% (n = 4)
- PKD 28% (n = 14) 15% (n = 14)
- Others 16% (n = 8) 16.1% (n = 15)
Transplants’ variables
DGF (%) 28%(n = 14) 30% (n = 28) 0.51
Cold ischemia time (h) 16.6 (SD = 3.72) 17.7 (SD = 5.2) 0.15
HLA MM (n = 47/50) (n = 89/93)
- 0 0% (n = 0) 0.01% (n = 1) 0.99
- 1 4% (n = 2) 5.3% (n = 5)
- 2 14% (n = 7) 18.2% (n = 17)
- 3 26% (n = 12) 25.8% (n = 24)
- 4 40% (n = 20) 36.5% (n = 34)
- 5 12% (n = 6) 8.6% (n = 8)
- 6 0% (n = 0) 0% (n = 0)
Biopsy Score (n = 48/50) (n = 82/93)
- 0 6% (n = 3) 3.2% (n = 3) 0.83
- 1 10% (n = 5) 8.6% (n = 8)
(Continued)
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addition, in the non-DGF group NGAL was able to distinguish between SGF and IGF with sta-
tistical significance. In the SGF group mean NGAL levels were 444.1±149.5 ng/ml vs. 307.8
±84.5 ng/ml in the IGF group (p<0.001). In the control population of 10 KT from living
donors (with very short CIT), mean NGAL levels were 67.3±25 ng/ml (Fig 3A). In the non-
DGF group, NGAL was further measured for 4 consecutive days after KT. In non-DGF patients
NGAL showed an earlier decrease in comparison to serum creatinine that remained stable or
even increased (Fig 4A and 4B). Furthermore, NGAL levels were evaluated in all enrolled
patients the day before and the day after Tac administration. The average time from transplan-
tation to CNI introduction was 11.04±4.86 days. Mean NGAL levels before and after Tac
administration were respectively 107.9±37.66 ng/ml and 155.9±48.3 ng/ml (p< 0.001—Fig 5).
By contrast, we did not find any significant difference between serum creatinine levels pre- and
post-Tac introduction (2.33±0.22 vs 2.38±0.31; p = 0.4 –data not shown in figs).
In vitro assays on TEC
Hypoxia and Tac increased NGAL expression in cultured human TEC. By using
qRT-PCR, we detected a significant increase of NGAL mRNA expression in TEC after 24h cul-
ture in hypoxic conditions and after 24h stimulation with 20 ng/ml Tac (p<0.001—Fig 6A,
amplification curve in S2 Fig). No significant differences in the housekeeping genes Beta-Actin
and GAPDH were observed in both hypoxic and Tac-stimulated TEC (data not shown).
The percentage of TEC producing NGAL measured by FACS showed an increase from 35%
(basal condition) to 94.2% and 89.6% after 24h of stimulation in hypoxic conditions and with
Tac, respectively (Fig 6B). NGAL was also measured by ELISA in TEC supernatants: hypoxia
induced a 4.05±0.53 fold increase (p<0.01), while 24h stimulation with Tac induced a 3.74
±0.71 fold increase (p<0.01—Fig 6C).
NGAL protected TEC from hypoxia- and Tac-induced apoptosis and functional alter-
ations. Culture in hypoxic conditions or incubation with 20 ng/ml Tac decreased viability
and increased apoptosis of TEC (p<0.001) (Fig 7). NGAL (500 ng/ml) significantly reduced
hypoxia- and Tac-induced cytotoxicity and apoptosis (Fig 7A and 7B, respectively). The spe-
cific role of NGAL was confirmed by experiments with TEC previously engineered by specific
siRNA to knock-down megalin, the NGAL receptor. Transfection of TEC with siRNA megalin
(qRT-PCR and western blot in S3 Fig) significantly reduced the anti-cytotoxic and anti-apo-
ptotic effect of NGAL. These results were not observed when TEC were transfected with an
irrelevant control siRNA (Fig 7). Moreover, we found that recombinant NGAL decreased the
Table 1. (Continued)
Study Group (n = 50) Other ECD KT (2013–2014) (n = 93) p
- 2 42% (n = 21) 33% (n = 31)
- 3 34% (n = 17) 29% (n = 27)
- 4 4% (n = 2) 10.7% (n = 10)
- >4 0% (n = 0) 3.2% (n = 3)
Analysis of clinical variables related to donors, recipients and transplant procedures in the study group of KT from ECD (n = 50) vs. all KT from ECD
(n = 93) performed in our center from 2013 to 2014. No significant differences between the two groups were observed. eGFR: estimated glomerular
filtration rate; BMI: body mass index; DGF: delayed graft function; HLA MM: HLA-mismatches; KT: kidney transplant; N-DGF: not delayed graft function;
PRA: panel reactive antibodies; pto: 24h proteinuria; sCr: serum creatinine; SD: standard deviation. The p values were calculated by t-student test for
continues variables, by χ2 test for other variables
*variable “dialysis duration” has not a normal distribution, thus the “p-value” was calculated with Mann-Whitney test.
doi:10.1371/journal.pone.0129279.t001
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Table 2. Comparison between DGF and non-DGF groups.
Study Group (n = 50) DGF (n = 14) non-DGF (n = 36) P
Donors’ variables
Age (years) 64.5 (SD = 8.5) 67.5 (SD = 7.25) 0.24
BMI (kg/m2) 26.3 (SD = 1.42) 25.2 (SD = 3.43) 0.985
eGFR (ml/min) 97.5 (SD = 25.3) 89.1 (SD = 26.6) 0.332
sCr (mg/dl) 0.76 (SD = 0.23) 0.79 (SD = 0.38) 0.722
Hypertension 57.1% (n = 8) 66.7% (n = 24) 0.67
Diabetes 14.2%% (n = 2) 8.3% (n = 3) 0.19
Death (n = 48)
- traumatic 50% (n = 6) 27.8% (n = 10) 0.18
- vascular 50% (n = 6) 72.7% (n = 26)
Recipients’ variables
Age (years) 54.5 (SD = 10.9) 57.5 (SD = 8.9) 0.333
BMI (kg/m2) 24.1 (SD = 3.59) 24.3 (SD = 3.77) 0.888
Hypertension 57.1% (n = 8) 75% (n = 27) 0.67
Diabetes 7.1% (n = 1) 21.6% (n = 8) 0.317
Dialysis duration (months) 81.9(SD = 110.2) 26.8 (SD = 39.9) 0.59*
Dialysis type
- hemodialysis 91.7%(n = 11) 75% (n = 27) 0.23
- peritoneal 8.3%(n = 1) 25% (n = 9)
PRA % 3.7 (SD = 14.7) 2.27 (SD = 6.32) 0.63
Gender
- male 57,1% (n = 8) 36.1% (n = 13) 0.532
- female 42.9% (n = 6) 63.9% (n = 23)
Previous KT 14.3% (n = 2) 8.3% (n = 3) 0.423
Discharge sCr (mg/dl) 2.08 (SD = 0.36) 1.89 (SD = 0.45) 0.157
Discharge pto (g/day) 0.56 (SD = 0.37) 0.58 (SD = 0.68) 0.726
Nephropathy (n = 13/14) (n = 36/36)
- glomerular 33.3% (n = 4) 16.2% (n = 6) 0.651
- tubule-interstitial 16.7% (n = 2) 10.8% (n = 4)
- vascular 8.3% (n = 1) 16.2% (n = 6)
- diabetes 0% (n = 0) 10.8% (n = 4)
- PKD 25% (n = 4) 29.7% (n = 10)
- others 15.4% (n = 2) 16.2% (n = 6)
Transplants’ variables
Cold ischemia time (h) 16.42 (SD = 3.95) 17.2 (SD = 2.95) 0.457
HLA MM (n = 11/14) (n = 36/36)
- 0 0% (n = 0) 0% (n = 0) 0.342
- 1 0% (n = 0) 5.5% (n = 2)
- 2 27.2%(n = 3) 11.1% (n = 4)
- 3 36.4% (n = 4) 22.2% (n = 8)
- 4 36.4% (n = 4) 44.4% (n = 16)
- 5 0% (n = 0) 16.6% (n = 6)
- 6 0% (n = 0) 0% (n = 0)
Biopsy Score (n = 12/14) (n = 36/36)
- 0 8.3% (n = 1) 5.5% (n = 2) 0.831
- 1 8.3% (n = 1) 11.1% (n = 4)
- 2 50% (n = 6) 41.7% (n = 15)
(Continued)
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expression of caspase-3, -8, -9 (Fig 8A) and the Bax/Bcl-2 ratio in TEC cultured in hypoxia or
with Tac (Fig 8B and 8C). These results suggest a putative role of NGAL in the inhibition of
both death receptor and mitochondrial pathways of TEC apoptosis.
Moreover, hypoxia and Tac induced in TEC loss of cell polarity assessed by trans-epithelial
electrical resistance (TEER in Fig 9A), reduction of albumin uptake (Fig 9B), down-regulation
of the tight junction protein ZO-1 (Fig 9C) and of the endocytic receptor megalin (Fig 9D). All
these functional changes were significantly decreased when 500ng/ml recombinant NGAL was
added to hypoxic and Tac-treated TEC.
Discussion
Previous studies showed a correlation between plasma and urine NGAL levels and DGF in KT
[21]. However, none of these studies were performed in KT from ECD and using CNI-sparing
protocols in the early phase after the procedure, with the impossibility to discriminate between
Table 2. (Continued)
Study Group (n = 50) DGF (n = 14) non-DGF (n = 36) P
- 3 25% (n = 3) 38.9% (n = 14)
-  4 8.3% (n = 1) 2.3% (n = 1)
Analysis of clinical variables related to donors, recipients and transplant procedures in the study group of KT from ECD (n = 50) subdivided between
patients with DGF (n = 13) and non-DGF (n = 37). No significant differences between DGF and non-DGF group were observed. eGFR: estimated
glomerular filtration rate; BMI: body mass index; DGF: delayed graft function; HLA MM: HLA-mismatches; KT: kidney transplant; N-DGF: not delayed graft
function; PRA: panel reactive antibodies; pto: 24h proteinuria; sCr: serum creatinine; SD: standard deviation. The p values were calculated by t-student
test for continues variables, by χ2 test for other variables
*variable “dialysis duration” has not a normal distribution, thus the “p-value” was calculated with Mann-Whitney test.
doi:10.1371/journal.pone.0129279.t002
Fig 2. Percentage of DGF risk estimated by the prediction algorithm proposed by Irish et al. (DGF calculator). No significant differences between DGF
and non-DGF KT patients were observed (p = 0.19, n = 50). DGF: delayed graft function.
doi:10.1371/journal.pone.0129279.g002
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ischemia-reperfusion injury and drug nephrotoxicity. We herein showed that the plasma level
of NGAL in the first 24h after KT from ECD without CNI therapy is an accurate biomarker for
DGF identification with sensitivity 92.9%, specificity 80.6% and AUC 0.94. Moreover, we
found that in non-DGF patients, NGAL was able to distinguish between SGF and IGF with sta-
tistical significance. NGAL was more sensitive than serum creatinine to predict functional
recovery. Indeed, we observed that NGAL levels decreased more rapidly than serum creatinine,
Fig 3. Evaluation of plasma NGAL levels at day 1 after KT in patients subdivided on the basis of graft function (DGF: Delayed Graft Function; SGF:
Slow Graft Function; IGF: Immediate Graft Function). (A) NGAL was significantly higher in DGF (662.7 ±97.2 ng/ml, n = 14) vs. non-DGF patients (SGF
+ IGF: 379.7±139.7 ng/ml, n = 36; #p<0.00001). A statistical significance was also observed comparing DGF vs SGF (444.1±149.5 ng/ml, n = 19; *p<0.001)
or IGF (307.8±101.8 ng/ml, n = 17; $p<0.00001) and SGF vs IGF (§p<0.01). NGAL levels of KT from living donors (LD) were used as control. (B) The Area
Under the ROC curve (AUC) of NGAL as biomarker of DGF at day 1 post-KT was 0.94.
doi:10.1371/journal.pone.0129279.g003
Fig 4. Evaluation of serum creatinine (sCr in A) and plasma NGAL (pNGAL in B) in the first 4 consecutive days after KT in non-DGF patients
(n = 36).NGAL significantly decreased starting from day 2 to day 4 after KT reaching a value near to normal levels (100 ng/ml). Each value of pNGAL was
significantly lower in comparison to the previous day (*p<0.05). By contrast, sCr remained stable or even increased (p>0.05).
doi:10.1371/journal.pone.0129279.g004
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suggesting re-establishment of both glomerular filtration and tubular re-absorption. Therefore,
these results suggest a potential use of NGAL determination for introducing CNI therapy even
though serum creatinine levels have not reached 2.5 mg/dl yet.
Another novelty of the present study was that NGAL offered a better monitoring of renal
response to Tac administration in comparison to serum creatinine. The use of NGAL as indica-
tor of CNI toxicity was recently proposed in cyclosporine-treated steroid-dependent nephrotic
children [22] but not in the context of KT. Furthermore, the in vitro studies provided informa-
tion on the functional role of NGAL indicating that its expression and release by human TEC
may have anti-apoptotic and regenerative effects.
Despite several causes are known to favor DGF, ischemia-reperfusion injury, CNI nephro-
toxicity and use of organs from ECD are recognized as main determinant factors [23,24]. Our
retrospective analysis confirmed a significant higher incidence of DGF in KT from ECD.
Indeed, the mean incidence of DGF in our study group was 26% despite the adoption of CNI
sparing protocols in the early phase after KT and to the policy of minimization of ischemia-
reperfusion injury (mean CIT of 16.42h).
The clinical relevance of DGF is associated with an increased risk of T cell-mediated rejec-
tion for the enhanced immunogenicity of TEC after ischemia-reperfusion injury due to expo-
sure of hidden antigens [25,26]. In addition, Fuquay et al. recently demonstrated that renal
ischemia-reperfusion injury may amplify the humoral immune response due to foreign antigen
Fig 5. Evaluation of plasma NGAL levels before and after Tacrolimus (Tac) introduction. NGAL was significantly higher after Tac administration (post-
Tac) than before drug introduction (pre-Tac) (*p<0.001, n = 50).
doi:10.1371/journal.pone.0129279.g005
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Fig 6. In vitro analysis of NGAL expression and release by human tubular epithelial cells (TEC) in different experimental conditions. Relative
quantification analysis (A) of NGALmRNA expression in TEC evaluated by qRT-PCR; mRNA expression of 3 different experiments was normalized for both
GAPDH (black columns) and Beta-Actin (white columns) after calculating housekeeping gene variation (see also methods). Hypoxia and 20 ng/ml
Tacrolimus (Tac) significantly increased NGALmRNA expression when compared to basal culture condition (Control, *p<0.001, #p<0.001). FACS (B) and
immunofluorescence (B inserts) analysis confirmed Hypoxia- and Tac-induced NGAL production. For FACS, Kolmogorov-Smirnov statistical analysis was
performed; control isotype antibody is represented by white plots, NGAL staining by black plots. For immunofluorescence analysis, nuclei were
counterstained with 1μg/ml propidium iodide, original magnification was x200. (C) ELISA analysis of NGAL released from TEC. Hypoxia and Tacrolimus
(Tac) significantly increased NGAL release in TEC supernatants (*p<0.01).
doi:10.1371/journal.pone.0129279.g006
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injection in mice, suggesting that DGF may also increase the risk of antibody-mediated rejec-
tion [27]. The association between ischemic and immune-mediated damage may lead to an
early deterioration of graft function that may be ascribed to development of aberrant mecha-
nisms of tubular repair and regeneration, finally leading to epithelial-to-mesenchymal transi-
tion and tissue fibrosis [28].
On the basis of the previous considerations, the development of early, accurate and nonin-
vasive biomarkers of graft function may facilitate DGF diagnosis. Several molecules identified
as indicators of acute renal dysfunction in native kidneys have been proposed for the detection
of DGF in KT. Among these, urine levels of IL-18 and NGAL have been shown to identify
DGF with acceptable statistical relevance [29]. However, in the majority of cases the low urine
output in the first hours after KT and the need of ratio with urine creatinine may generate
some interpretative bias. For these reasons, we decided to study plasma levels of NGAL, a
25KDa protein belonging to the lipocalin family. Lipocalins, together with avidins and fatty
acid binding proteins, constitute the calycin superfamily, a class of low-molecular weight pro-
teins characterized by a hydrophobic binding site [30]. The main biological function of NGAL
is the transport of iron through small molecules called siderophora. During infections, neutro-
phils release NGAL to regain iron chelated by bacterial siderophora with a consequent bacteri-
ostatic activity. Moreover, during embryogenesis and tissue damage NGAL is known to
promote differentiation and regeneration processes by iron delivery. The plasma pool of
NGAL is mainly composed by the quote released by neutrophils, monocytes and hepatocytes
that is freely filtered by glomeruli for its low molecular weight and re-adsorbed by proximal
TEC through a megalin-dependent mechanism [31]. The urine pool of NGAL is composed by
the quote not re-uptaken by proximal TEC and by a further quote produced in the distal part
of the nephron as a consequence of ischemic or toxic tubular injury [31]. Moreover, plasma
NGAL levels are strongly influenced by the presence of a chronic impairment of renal function
and of an inflammatory state [32]. Our experience confirmed this observation: pre-transplant
NGAL levels were high and comparable to those detected in the DGF group.
Fig 7. In vitro analysis of TEC cytotoxicity (XTT assay in A) and apoptosis (TUNEL assay in B) in different experimental conditions. Hypoxia and Tac
(20 ng/ml) significantly increased cytotoxicity (A, *p<0.01) and apoptosis (B, *p<0.01) in wild type TEC (white bars). NGAL (500 ng/ml) significantly
decreased both hypoxia- and Tac-induced TEC cytotoxicity (A: #p<0.01, §p<0.05); and apoptosis (B: #p<0.01, §p<0.05). This effect was not observed after
megalin knock-down by siRNA (siRNAMegalin in black bars) but not by transfection with an irrelevant siRNA (siRNA CTRL in gray bars).
doi:10.1371/journal.pone.0129279.g007
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Fig 8. (A) ELISA for caspase-3, -8 and -9 activity in TEC cultured in different experimental condition. Hypoxia and Tac (20 ng/ml) significantly increased
caspase-3, -8, -9 activity (*p<0.05). NGAL (500 ng/ml) significantly decreased both hypoxia- (#p<0.05) and Tac-induced (§p<0.05) caspase-3, -8, -9 activity.
(B) Western Blot analysis of Bax/Bcl2 and relative quantitative analysis expressed as Bax/Bcl2 ratio. Hypoxia and Tac (20 ng/ml) increased Bax/Bcl2 ratio.
NGAL (500 ng/ml) decreased both Bax/Bcl2 ratio. Values of Bax and Bcl2 were previously normalized for Beta-Actin expression. Three different experiments
were performed with similar results.
doi:10.1371/journal.pone.0129279.g008
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NGAL production has been shown to be up-regulated in different experimental models of
TEC injury as well as in AKI patients. However, the biological activity of NGAL on TEC still
remains controversial. Following nephron reduction, NGAL knock-out mice presented a signifi-
cant decrease of proliferative renal lesions in respect to wild type animals [33]. NGAL expression
was up-regulated after EGFR activation through a mechanism dependent on HIF-1αmodula-
tion. These results were confirmed in human CKD in which NGAL was particularly increased in
patients with a rapid progression toward end stage renal failure. Taken together, these findings
suggest that NGALmay be a reliable marker of tubular de-differentiation playing a role in the
aberrant mechanisms of tissue repair and promotion of fibrosis already reported for other AKI
biomarkers such as KIM-1 [34]. By contrast, other studies demonstrated that NGALmay act as
a growth and differentiation factor in several cell types including renal epithelial cells [35]. This
effect may be ascribed to the up-regulation of heme oxygenase-1 and to the consequent inhibi-
tion of cell death induced by oxidative stress [7,36]. In the present study, we observed that
NGAL significantly reduced hypoxia-associated in vitro human TEC apoptosis through the inhi-
bition of caspase activation and the reduction of Bax/Bcl-2 ratio. These results are in accordance
with previous studies showing that NGAL inhibited apoptosis and bax/caspase-3 expression in a
rat experimental model of renal artery ligation [10]. We also found that NGAL exerted on Tac-
treated TEC a proliferative and anti-apoptotic effect similar to that observed in hypoxic
Fig 9. TEC functional assays after hypoxia or Tac. (A) Analysis of TEC polarity assessed by trans-epithelial electrical resistance (TEER) in different
experimental conditions. Hypoxia and Tac (20 ng/ml) significantly decreased TEER (*p<0.05). NGAL (500 ng/ml) significantly increased TEER in both
hypoxia- (#p<0.05) and Tac-treated (§p<0.05) TEC. (B) Analysis of uptake of FITC-conjugated albumin by TEC in different experimental conditions. Hypoxia
and Tac (20 ng/ml) significantly decreased albumin uptake (*p<0.05). NGAL (500 ng/ml) significantly increased albumin uptake in both hypoxia- (#p<0.05)
and Tac-treated (§p<0.05) TEC. (C-D) FACS analysis of the tight junction molecule ZO-1 (C) and of the endocytic receptor megalin (D) in TEC cultured in
different experimental conditions. Hypoxia and Tac significantly decreased ZO-1 and megalin expression. NGAL (500 ng/ml) up-regulated ZO-1 and megalin
in both hypoxia- and Tac-treated TEC. Kolomogorov Smirnov statistical analysis was performed in three different experiments with similar results.
doi:10.1371/journal.pone.0129279.g009
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condition, suggesting a putative beneficial role of this iron carrier molecule on both ischemic
and nephrotoxic injury. Furthermore, NGAL preserved cell polarity and function in hypoxic
and Tac-treated TEC as assessed by TEER, albumin uptake and staining for the endocytic recep-
tor megalin and for the tight junction protein ZO-1. All these biological activities were observed
in vitro using NGAL concentrations similar to those observed in KT patients. In addition, these
effects were specific for NGAL, since siRNA-induced knock-down of megalin, the main NGAL
receptor located on TEC surface, significantly abrogated its protective actions.
In conclusion, we demonstrated that NGAL is an early and accurate biomarker of graft
function in KT from ECD. Moreover, NGAL is able to discriminate DGF from SGF or IGF
with high sensitivity and specificity and it seems to be more sensitive than serum creatinine for
monitoring Tac toxicity. Finally, our in vitro studies suggested that TEC may react to injurious
stimuli triggering NGAL production via an autocrine loop aimed to sustain cell proliferation
and inhibition of apoptosis associated with iron uptake.
Supporting Information
S1 Dataset. Clinical and experimental data. Dataset is organized in 9 sections; each section
displays data of corresponding figs.
(XLSX)
S1 Fig. In vitro analysis of cytotoxicity (XTT assay) of TEC cultured in hypoxic condition.
Recombinant NGAL significantly increased hypoxic TEC viability in a dose-dependent man-
ner starting from 100 ng/ml (p<0.001). The highest level of NGAL-induced TEC proliferation
was observed using 500 ng/ml (p<0.001).
(TIF)
S2 Fig. Representative amplification curve of NGAL mRNA expression by quantitative
Real Time PCR (q-RT-PCR): in basal conditions (Control), in hypoxic conditions (Hyp-
oxia) or with Tacrolimus (Tac).
(TIF)
S3 Fig. Quantification by qRT-PCR (A) and western blot analysis (B) of megalin in wild
type TEC or in TEC transfected with 80 pM siRNA (siRNA megalin) or with 80 pM control
siRNA (siRNA control). For qRT-PCR, megalin mRNA levels were normalized for the house-
keeping gene Beta-Actin. For western blot analysis, megalin protein levels were normalized for
Beta-Actin (Actin).
(TIF)
S1 File. FACS Analysis and RNA Interference (Method). For FACS analysis, cells were
detached with EDTA and stained for 1 h at 4°C with a primary antibody directed to human
NGAL, Megalin, ZO-1 or with an irrelevant control antibody. After extensive washing, cells
were incubated with Alexa Fluor—conjugated secondary antibodies for 45 min at 4°C where
appropriate. All incubation periods were performed using a medium containing 0.25% BSA
and 0.0016% sodium azide. At the end of staining, cells were newly washed, fixed in 1% para-
formaldehyde, and subjected to FACS analysis (Becton Dickinson, Mountain View, CA). In
selected experiments, TEC were seeded on six-well plates and Megalin siRNA, or relative con-
trol siRNA (80 pM) was introduced according to the manufacturer’s instructions (Santa Cruz
Biotechnology). After 48 h, the effective suppression of specific mRNA and proteins was veri-
fied by RT-PCR, by WB and by citofluorimetric analysis (unpublished data). Subsequently, the
cells were used to evaluate proliferation and apoptosis.
(DOCX)
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